Pressemitteilung BoxID: 734560 (aap Implantate AG)
  • aap Implantate AG
  • Lorenzweg 5
  • 12099 Berlin
  • Ansprechpartner
  • Fabian Franke
  • +49 (30) 75019-134

aap: Successful start in 2015 with 45% LOQTEQ® sales increase and 23% growth in biomaterials business

(PresseBox) (Berlin, ) aap Implantate AG (XETRA: AAQ.DE) made a successful start to financial year 2015 with significant sales growth. According to preliminary figures, sales increased in the first three months of this year compared to the corresponding period in the last year by 16% to EUR 7.1 million (Q1/2014: EUR 6.1 million). Thereby the company exceeded its guidance provided in February of EUR 6.5 million to EUR 7.0 million.

The growth drivers of this positive sales performance in the first three months of the current financial year were the LOQTEQ® product family and the biomaterials business. aap Implantate AG significantly increased sales with the LOQTEQ® portfolio in the first quarter of 2015 year-on-year by 45% to EUR 1.7 million (Q1/2014: EUR 1.1 million). Performance in the reporting period testifies to the anatomic plate system continuing to establish itself in the market.

Sustained by the significant growth in LOQTEQ® product sales, aap Implantate AG's overall sales in the trauma business rose year-on-year by 15% to EUR 2.5 million (Q1/2014: EUR 2.2 million). On a full year basis the company's target is to achieve sales growth of more than 20% in the trauma business. In order to achieve this target, aap Implantate AG intends to expand the LOQTEQ® product family further in the current financial year and thereby achieving an indication coverage of more than 90%. Furthermore the company plans to push the internationalisation with a focus on the US American market.

In the biomaterials business the company also achieved a significant sales increase in the first quarter of 2015. Sales grew in the reporting period compared to the first three months of financial year 2014 by 23% to EUR 4.4 million (Q1/2014: EUR 3.6 million). The growth driver in the first quarter of the current year was in particular the bone cement business with global leading companies.

Overall, it can be furthermore stated that aap Implantate AG generates dynamic sales growth and pushes geographic expansion with its innovative and IP protected LOQTEQ® products, while the biomaterials business is characterized by continuous and profitable growth with strong cash flows.

The preliminary results contained in this press release are based on management's initial analysis of operations for the period ended on 31 March 2015, and are therefore subject to change. aap Implantate AG plans to announce its final results for the first quarter of 2015 on 15 May 2015.